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The most recent guidelines define COPD in a multidimensional way, nevertheless the diagnosis is still linked to the
limitation of airflow, usually measured by the reduction in the FEV1/FVC ratio below 70%. However, the severity of
obstruction is not directly correlated to symptoms or to invalidity determined by COPD. Thus, besides respiratory
function, COPD should be evaluated based on symptoms, frequency and severity of exacerbations, patient’s functional
status and health related quality of life (HRQoL). Therapy is mainly aimed at increasing exercise tolerance and reducing
dyspnea, with improvement of daily activities and HRQoL. This can be accomplished by a drug-induced reduction of
pulmonary hyperinflation and exacerbations frequency and severity. All guidelines recommend bronchodilators as
baseline therapy for all stages of COPD, and long-acting inhaled bronchodilators, both beta-2 agonist (LABA)
and antimuscarinic (LAMA) drugs, are the most effective in regular treatment in the clinically stable phase. The
effectiveness of bronchodilators should be evaluated in terms of functional (relief of bronchial obstruction and
pulmonary hyperinflation), symptomatic (exercise tolerance and HRQoL), and clinical improvement (reduction in
number or severity of exacerbations), while the absence of a spirometric response is not a reason for interrupting
treatment, if there is subjective improvement in symptoms. Because LABA and LAMA act via different mechanisms of
action, when administered in combination they can exert additional effects, thus optimizing (i.e. maximizing) sustained
bronchodilation in COPD patients with severe airflow limitation, who cannot benefit (or can get only partial benefit) by
therapy with a single bronchodilator. Recently, a fixed combination of ultra LABA/LAMA (indacaterol/glycopyrronium)
has shown that it is possible to get a stable and persistent bronchodilation, which can help in avoiding undesirable
fluctuations of bronchial calibre.
Keywords: Bronchodilation, COPD, Dyspnea, Exercise tolerance, Fixed combination indacaterol/glycopyrronium,
HRQoL, Hyperinflation, LABA, LAMAReview
Although the AGENAS guidelines (http://www.agenas.it/
images/agenas/pnlg/BPCO.pdf), the inter-societal document
(http://www.aimarnet.it/wordpress/up-contente/uploads/
2013/11/Gestione-BPCO_04_layout-1-blk.pdf) and the lat-
est GOLD guidelines define COPD in a multidimensional
way, for its diagnosis it is still necessary to detect a functional
characteristic: the limitation of airflow, usually measured by
the reduction in the FEV1/FVC ratio below 70%.
Obstructive abnormalities of the small airways with a
reduction in their caliber and destructive phenomena of
the parenchyma with reduced lung elastic recoil, represent
the two pathophysiological mechanisms responsible for
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unless otherwise stated.The fact that the small airways are the compartment
where the histopathological damage occurs for the two
above cited mechanisms, was demonstrated many years
ago in a group of COPD patients who died because of
cardiac failure. The prevalence of one of the two histo-
pathological alterations (bronchial inflammation or par-
enchymal destruction) corresponded to different clinical
phenotypes: these were functionally distinguished by a
different alteration of the parameters indicative of hyper-
inflation and impaired gas exchange more than by the
parameters indicative of obstruction [1].
Another important pathophysiological consequence of
the bronchial tree involvement in COPD is the marked
increase in resistance, up to 40 times more than normal,
due to the presence of mucus hypersecretion, with ob-
struction and obliteration of the small airways. The conse-
quence is that the time needed for these obstructed lungLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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their passive equilibrium point at the end of a normal
expiration maneuver, is significantly increased. Many of
those units do not reach their relaxation volume before a
new inspiration is initiated. As a result, part of the gas that
would have been expired in a normal lung, remains
“trapped” in patients with COPD causing hyperinflation.
This condition is more severe during exercise, when more
and more units are unable to empty (or wash-out) their
gas, as expiratory time decreases when the respiratory rate
increases and such hyperinflation represents the patho-
physyological basis of dyspnea on effort that is the most
invalidating symptom in COPD.
The critical points of the physiopathological approach
to the illness can be summarized in this way:
– the FEV1/FVC is an index of bronchial obstruction
that does not reflect alterations in the small caliber
airways described by pathological anatomy and
already present in the first phases of the illness;
FEV1 does not define the prevalent phenotype of the
illness
– the study of the peripheral airways is not easily done
in a normal clinical routine
– the distal airway involvement is associated with
increased static lung volumes (hyperinflation), as well
as destruction of the vascular capillary pulmonary
zone and alterations in gas exchange. All these
physiopathological alterations together are responsible
for the symptoms and clinical course of the illness
– COPD is a complex illness that goes beyond the
simple functional definition. The contribution of
pathophysiology to this definition cannot, however,
disregard to perform a global spirometry test and a
diffusion test
Is bronchial obstruction a necessary and sufficient
condition for a COPD diagnosis?
The spirometric evidence of a not completely reversible
obstruction is a necessary condition for the diagnosis of
COPD which could be better supported by a nitrogen
wash-out test. However, the seriousness of the obstruc-
tion is not directly correlated to the symptoms or inval-
idity determined by the COPD; indeed, “similar levels of
obstruction can correspond to very different levels of
invalidity and prognosis” [2].
The seriousness of the patient’s condition appears to
be determined not only by the deterioration of pulmon-
ary function, but also by the symptoms, the propensity
for exacerbations, the nutritional status, and the pres-
ence of other diseases (comorbidities) [3].
Therefore, even COPD’s progression should be evalu-
ated and monitored not only with regards to respiratory
function, but also looking at other parameters, such asthe type and intensity of symptoms, the frequency and
severity of exacerbations, the functional status of the
patient, the use of drugs and the quality of life.
Which pathophysiological parameters is bronchial
obstruction evaluated on?
1) There are two criteria to evaluate bronchial
obstruction: “Fixed ratio” (FEV1/FVC <70%) and
“Lower limit of normal (LLN, measured value below
the 5th percentile of a healthy population, made up
of non-smokers).” The first one is more practical,
but it is said to generate under-diagnosis in young
people and over-diagnosis in the elderly. The second
one, could be more precise, but there are few or no
reliable estimates of the distribution of the FEV1/FVC
ratio in the various age ranges [4]. Given that COPD
diagnosis - particularly in the elderly - is never only
spirometry-based and diagnostic suspicion - generated
by symptoms and individual risk-profile - precedes
the spirometry, the potential diagnostic error of
employing the fixed ratio will be reduced by the
clinical evaluation leading to the spirometry test [4].
Once the patient has been profiled, what is expected
from medical therapies?
It is necessary to remember that the three stakeholders
of the diagnostic process are: the patient (the central
element), the medical team and the health institutions
or rather the “taxpayers” Expectations often coincide,
but not always are the same. For example, a functional
improvement is an objective which is justifiably pursued
by the physician, but it does not represent the primary
objective for the patient, who is more interested in an
improvement in symptoms and in keeping the therapy
as simple and safe as possible.
The improvements expected by the patient are therefore
an increased tolerance for physical exercise and a reduc-
tion of dyspnea, because these reflect positively on daily
activities and quality of life. Physical activity and muscular
force, already lessened in the initial phases of COPD,
continue to decrease as the disease progresses [5-7].
On the other hand, the reduction in physical activity is
the strongest predictor of mortality for all causes in
COPD patients (Figure 1) [8] and is correlated among
others to dynamic hyperinflation [9].
As a consequence, the reduction of pulmonary hyper-
inflation increases the tolerance to exercise and there-
fore physical activity [10,11]; in this context one could
fancy a positive effect on survival, even if at this point
there is no scientific evidences to confirm this theory.
The improvement in capacity is one of the key results
obtained through pulmonary rehabilitation, as stated in
abundant literature and recent guidelines (ATS/ERS,
Nice) [12,13], but the use of “desufflating medications”,
Figure 1 Comparison between relative risk of death associated with physical activity and established predictors of mortality.
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rehabilitation itself [14].How to obtain bronchodilation
Routes to obtain bronchodilation
The reduction of resistance in the airways depends on
factors both intrinsic and extrinsic to them, being
constituted by smooth muscle relaxation, reduction of
inflammation of the bronchial and bronchiolar wall, and
reduction of secretions.
Airway smooth muscle relaxation can be obtained by
two main pharmacologic strategies: directly through stimu-
lation of β2-adrenoceptors (β2-ARs) with β-agonists orSmooth muscle
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Figure 2 Mechanisms of bronchodilatory action of antimuscarinic age
the binding of acetilcholine (ACh) to M3 muscarinic receptor, thereby inhib
agonists bind to beta2-adrenergic receptor and induce a cascade of signalindirectly by inhibiting acetylcholine signaling via muscar-
inic receptors with muscarinic antagonists (Figure 2).
The first one is based on the use of β2-adrenoceptors
agonists, that, by binding to the β2-adrenoceptor receptors
on the surface of the smooth muscle cells in the airways,
including small ones, directly determine the relaxation and
the consequent bronchodilation [15].
The cellular mechanism at the basis of bronchodila-
tion involves the activation of the adenylcyclase and the
generation of intracellular cAMP, which then activates
the effector molecules protein-kinase A (PKA) and Epac
(effector of cAMP).
In turn, the PKA works through phosphorylation of
the proteins that control smooth muscle tone, the EpacRelaxation
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ently of PKA and the cyclical AMP sequesters the intra-
cellular Ca, all of this having, as a consequence, smooth
muscle relaxation [16,17].
The second one is based on the use of antimuscarinics,
which act indirectly, competitively antagonizing the
receptors of the contractile agonist (ACh).
The parasympathetic activity in the airways is, in fact,
mediated by the muscarinic receptors M1 and M3,
whose stimulation produces the contraction of the
smooth muscle, mucus secretion and increase in ciliary
activity, and from the M2 receptors, which instead inhibit
the release of ACh from the nerve endings [Figure 3].
The increase in cholinergic bronchomotor tone is con-
sidered important to the pathogenesis of COPD, contrib-
uting to the increase in bronchial obstruction through
bronchoconstriction and mucus hypersecretion [18,19].
β2-adrenergic receptor agonists bind to β2-ARs on the
surface of smooth muscle cells at all airway levels, even
in the small airways involved in COPD. Antimuscarinic
agents antagonize muscarinic (M3) receptors on airway
smooth muscle and thereby prevent smooth muscle con-
traction. Though a direct vagal innervation is absent in
the small airways, muscarinic receptors are present in
the small airways and are likely activated by extra neur-
onal acetylcholine in diseases such as COPD. Therefore,
antimuscarinic agents could dilate both large and small
airways. The traditional separation of β2-agonists acting
on the distal airways and antimuscarinics acting on the
proximal airways is likely to be revisited and a combin-
ation therapy with both classes of drugs may provide
greater bronchodilation at all airway levels than either
component alone. Two different mechanisms of broncho-
constriction have the potential to maximize the broncho-
dilator response and can help to overcome the inter- andFigure 3 Presynaptic mediator involved in ACh release
(neurojunctional plaque). Modified from [71,72].intra-patient variability in response to individual agents
often observed in patients with COPD. Furthermore, it
can be expected that an antimuscarinic agent together
with a long-acting β-2, “thus combining different mecha-
nisms”, can have a synergistic effect on tolerance to phys-
ical activity, on daily activities and on the quality of life
which, as stated before, is also linked to simple adminis-
tration of drugs.
Analyzing the literature regarding the most recent
bronchodilators available for the treatment of COPD, it
should be noted that the first ultra-long acting β-2
stimulant, indacaterol, is currently the only LABA with a
single daily administration and it has been demonstrated
to be superior to other bronchodilators in reducing pul-
monary hyperinflation [20] and dyspnea and increasing
ability to exercise [21]. With regards to recent anticholin-
ergics that enriched this segment, glycopyrronium (also a
once-daily drug) demonstrated a notable improvement in
endurance [11].Bronchodilators: how, where and when?
All guidelines for COPD declare bronchodilators as the
baseline therapy for all stages of COPD. Instead, the
choice of bronchodilator with which to start treatment
is left up to the doctor in all guidelines (CTS, GOLD,
AGE.NA.S, ACP/ACCP/ATS/ERS). Numerous system-
atic revisions have compared the efficacy of the treat-
ment of inhalers for COPD with placebo and among
themselves.
In an editorial written in 2011 by J.A. Wedzicha, while
commenting the results of the POET study, it was
argued that the initial therapeutic choice depends on the
patient characteristics and thus LAMA in monodoses
might be more indicated than LABA with the objective
of reducing the number of exacerbations even if the
comparison is unfair due to the fact that in that study
tiotropium has a duration of 24 hours and salmeterol
only 12. In fact, the comparison between uidtiotropium
and ultra_LABAindacaterol shows that these drugs have
comparable results for bronchodilation as well as symp-
toms, quality of life and relapses [22-24].
The combination of ICS/LABA compared with LAMAs
has given contrasting results. For example, the exacerba-
tions treated with steroids are more frequent in patients
treated with LAMA, while in those using ICS/LABA treat-
ments with antibiotics and pneumonia are more common,
while hospitalizations were not significantly different in
either of the two methods of treatment [25].
The analysis of the studies that compared LABA with
ICS treatment confirms the current guidelines that fore-
see initial treatment with long-acting bronchodilation
along with the addition of steroid inhalers for patients
with frequent exacerbations [26].
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with 12 h (salmetorol and formetorol) or 24 h (ultra-
LABA indacaterol) duration. Various studies have demon-
strated that LABA reduce hospitalizations and dyspnea
and increase lung function and quality of life. The safety
profile of LABAswas comparable to placebo [27].
In general, long-acting bronchodilators have been
proven to be able to produce a long-lasting improve-
ment in lung function and quality of life and to reduce
relapses in patients with COPD. They are also able to
reduce hyperinflation and therefore to improve dyspnea
and tolerance to physical activity [10,28-32].
Moreover, it has been recently demonstrated that the
co-formulation of LAMAs and LABAs improves the
quality of life, increases FEV1, reduces dyspnea and re-
lapses, compared to monotherapies (Shine study) [33].
The increasing number of drugs for COPD, both single
and combined, increases on one side the number of
therapeutical options, but on the other makes the choice
more complicated. Further studies should be designed to
give necessary evidence to the optimal sequence of
monotherapy and the combination of bronchodilators to
use in an algorithm of treatment for COPD [34-38].
Role of anticholinergic bronchodilators: effectiveness and
safety
Inhaled bronchodilators, with long-lasting action, are the
most effective drugs in the regular treatment of COPD in
the clinically stable phase. To control or improve symp-
toms and health, these are more effective and simpler to
be used than short-acting bronchodilators, improving
therefore the adherence to chronic therapy as well [39].
The effectiveness of bronchodilators should be evalu-
ated not only in terms of functional improvement (of
the bronchial obstruction and pulmonary hyperinflation)
but also in terms of relieve from symptoms (exercise
tolerance and quality of life), and clinical improvement
(reduction in number or severity of exacerbations), so
that the absence of a spirometric response is not a
reason for interrupting treatment, if there is subjective
improvement in symptoms.
LAMAs (long-acting antimuscarinic agents) contrast
excessive activity of the parasympathetic system, which
has the fundamental function of regulating bronchial
smooth muscular tone and prevents the inhalation of
potentially irritating substances (such as atmospheric
particles and cigarette smoke), thanks to a momentary
increase in bronchial tone, with a consequent broncho-
constriction. When, due to exogenous stimuli, the increase
in bronchial tone becomes excessive and/or permanent,
therapy with LAMA can be favorable.
Recent LAMAs act by impeding the bronchial
obstruction for a prolonged period of time. The LAMAs
have two characteristics, their binding to the receptorand kinetic selectivity, in other words, the capability to
bind to- but also to leave- the receptor.
Clinically relevant muscarinic receptors are substan-
tially of two types, M2 and M3. The M3 muscarinic
receptors are variously located within the organism, but
their concentration within the lung is particularly high.
The M2 receptors are largely present in the cardiac
muscle cells and, therefore, their prolonged stimulation
could induce unwanted cardiological events. Selectivity
in action is therefore capital.
Recently, Glycopyrronium bromide demonstrated to
be an antagonist of long-action muscarinic receptors,
which act by blocking the bronchoconstricting action
mediated by the parasympathetic system and by the
nervous fibers that release acetylcholine at the smooth
muscle cell level in the airways. It showed a decisively
greater selectivity (approximately 4 times) for human
receptors M3 respect to M2 receptors [40].
Glycopyrronium has been evaluated in three phase III
studies in which 2,700 patients were studied and it
showed significant superiority compared to the placebo
in improving respiratory function, measured with FEV1
(p <0.01), after 12 weeks of treatment. Glycopyrronium
also showed a functional effectiveness (FEV1) similar to
Tiotropium, during the 52 weeks of the GLOW2 study.
Apart from demonstrating benefits for pulmonary func-
tion, Glycopyrronium showed a rapid onset of action,
within 5 minutes from the first inhalation [41,42].
The administration of the drug has also been shown to
be effective in reducing the number of acute exacerba-
tions of the illness.
Benefits have also been demonstrated with respect to
the placebo, both for dyspnea and quality of life, mea-
sured with the TDI (Transition Dyspnea Index) scale
and the SGRQ (St. George’s Respiratory Questionnaire),
respectively. After the morning administration of Glyco-
pyrronium, patients have benefitted from an improved
resistance to physical activity, from the first doses on. In
general, patients treated with Glycopyrronium presented
an improvement in physical activity 21% higher than
those with the placebo at the end of the study (day 21),
with a significant increase of 10% from the first day
(both p <0.001) [11].
In all the studies, patients, in the glycopyrronium-arm,
demonstrated a drug-tolerance similar to that of the
placebo, and the incidence of adverse events was also
similar to the placebo [43,44].
Role of β-2 agonist bronchodilators: effectiveness and
safety
β-2 agonist bronchodilators act mainly by relaxing the
smooth muscle of the airways by binding with specific
cellular receptors and through the activation of the ade-
nylatecyclise [16]. For over 15 years the long-acting β-2
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terol have been used in COPD therapy in stable phase.
Both have a duration of approximately 12 hours [45]
and they were demonstrated to be more effective that
the short-acting β-2 agonist (SABA) in improving symp-
toms, respiratory function (FEV1), and tolerance to exer-
cise in patients with COPD [46-48] even through the
reduction of dynamic hyperinflation [49]. Various stud-
ies, including the mega-trial TORCH [50], have shown a
reduction in the number of COPD exacerbations with
the use of formoterol and salmeterol vs placebo [51,52].
As already noted in studies of patients with bronchial
asthma, formoterol produces a bronchodilation more
rapidly than salmeterol [53]. However, there is still not
sufficient data to prefer one of these LABA in mainten-
ance therapy for COPD [54].
Indacaterol, the first “ultra-LABA” with an active dur-
ation of over 24 hours, has been available since 2010. Its
characteristic allows mono- administration, which, along
with a rapid onset of action, similar to formoterol and
salbutamol, makes it potentially useful in increasing
patient compliance [55]. The mechanism at the basis of
indacaterol properties (rapid onset of action and persist-
ence of effect) is still not fully clear; it is hypothesized
that this depends on its peculiar interaction with the
lipid membrane of the airways smooth muscle cells and
on its greater capacity of diffusion in the lipophilic
compartments after inhalation, with respect to previous
generation of LABAs [56,57].
Whatever the mechanism involved, indacaterol, when
compared with various long-acting bronchodilators for
the treatment of COPD, shows to be superior to for-
moterol and salmeterol with regards to effects on
FEV1 and symptoms [58,59] and comparable or super-
ior to tiotropium when the duration of bronchodila-
tion (trough FEV1), symptoms and quality of life have
been considered [55,60].
A recent meta-analysis of 20 randomized studies
controlled with a placebo, conducted on a total of 8,774
patients with COPD, with a duration of at least 6 months
(10 with formoterol, 9 with salmeterol and 4 with inda-
caterol) did not demonstrate differences in the major
adverse events (in particular cardiovascular) between
the group treated with LABA and the placebo. In 1% of
patients there were events noted which are traditionally
associated with the use of β-2 agonists (muscle tremors,
palpitations), the systemic effects correlated to the stimu-
lation of β-2 agonist receptors (hyperglycemia, hypokal-
emia) should be considered of a lesser clinical relevance
[61]. However, a retrospective study of control cases in
elderly COPD patients (over 67 years-old) that had devel-
oped severe cardiac arrhythmias (cases) vs those that had
not (controls) demonstrated that the development of ar-
rhythmias was more associated to the use of LABA(formoterol and salmeterol) with rate/ratio 1,47 [62]. So,
as underlined in the guidelines, the use of LABA should
always be carefully evaluated with attention in COPD
patients with cardiovascular comorbidity or arrhythmias.
Why and how to maximize bronchodilation
Because LABA and LAMA act via different mechanisms
of action, they can exert additional bronchodilating ef-
fects, thus being able together to optimize and maximize
pharmacologic bronchodilation in those COPD patients
with severe airflow limitation, whose needs cannot be
satisfied by monotherapy with a single, either LABA or
LAMA bronchodilator. Therefore, current International
and National guidelines (GOLD, AGE.NA.S, GARD) rec-
ommend the association of two long-acting bronchodila-
tors when only one is not sufficient to provide satisfactory
symptom relief [63]. In particular, indacaterol and glyco-
pyrronium show to give very fast and long-lasting (about
24 hours) relaxation of airway smooth muscle [64-66].
These pharmacodynamic properties can provide, with a
single daily administration, a stable and persistent bron-
chodilation avoiding fluctuations of bronchial calibre, in a
way which has been colourfully defined as “pharmaco-
logical airway stenting”. On these grounds, the single-
inhaler, indacaterol/glycopyrronium in fixed combination
could be very effective in reducing dynamic lung hyperin-
flation as well as increasing compliance. We can assume
that LABA and LAMA could exert their combined
bronchodilating action also at the level of small airways,
so counteracting one of the most important factors limit-
ing exercise capacity in COPD such as air trapping, and
decreasing dyspnea perception, and finally improving
QoL. In addition, the sustained reduction in lung hyperin-
flation secondary to the decreased airway resistance, also
given by LABA/LAMA associations, can also contribute
to prevent COPD exacerbations [67]. In fact, improve-
ments in lung hyperinflation are correlated with positive
effects on frequency and severity of COPD exacerbations,
probably due to a better re-setting of lung function
dynamics elicited by long-acting bronchodilation.
The pharmacological basis of the reciprocal cooperation
between LABA and LAMA is very strong. Indeed, LABA
induce bronchodilation by relaxing airway smooth muscle
regardless of the constricting stimuli, thus acting as func-
tional antagonists of bronchoconstriction. On the other
hand, LAMA inhibit the bronchoconstrictive effects of
acetylcholine acting via a competitive antagonism of mus-
carinic receptors, thus complementing, integrating and
potentiating the functional antagonism elicited by LABA
[63]. As for selectivity, glycopyrronium exhibits a high
kinetic selectivity for M3 versus M2 muscarinic recep-
tors, while bronchodilator features depend on the power-
ful and prolonged blockade of M3 receptors, which in
human airways are predominantly responsible for the
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more, the high degree of kinetic selectivity for M3 over
M2 muscarinic receptors makes it possible for glycopyr-
ronium to rapidly dissociate from M2 receptors, which
within the airways inhibit the release of acetylcholine
from postganglionic parasympathetic fibres. Therefore,
the positive interactions between indacaterol and glyco-
pyrronium extend from post-junctional, airway smooth
muscle level, to pre-junctional, nerve terminal level,
where the inhibitory effect on acetylcholine release me-
diated by stimulation of β2-adrenergic receptors con-
verges with the analogous action exerted by activation
of M2 muscarinic receptors, whose function is greatly
spared by glycopyrronium. The therapeutic advantages
of a fixed combination of LABA-LAMA, namely the one
of indacaterol (110 μg)/glycopyrronium (50 μg), have been
recently demonstrated by several clinical trials, including
ENLIGHTEN, ILLUMINATE, SPARK and SHINE studies
[33,68-70], confirming what has been forecasted by guide-
lines as more effective of single-drug treatment.Safety of the co-formulation of LAMAs and LABAs
Combination of LAMAs and LABAs offer the poten-
tial of improved convenience and compliance over use
of separate inhalers [71,72]. The dose of each agent to
be used in combination can be optimized. A major
challenge in the development of combinations is
provision of improved bronchodilation over mono-
therapy components while balancing the associated
adverse events.Table 1 Adverse events, serious adverse events, deaths and d
Placebo QVA149110/50 μg
Subjects, n 232 474
Patients with any adverse events 134 (57.8) 261 (55.1)
COPD 91 (39.2) 137 (28.9)
Nasopharyngitis 23 (9.9) 31 (6.5)
Cough 8 (3.4) 26 (5.5)
Upper respiratory tract infection 13 (5.6) 20 (4.2)
Oropharyngeal pain 7 (3.0) 17 (3.6)
Viral upper respiratory tract infection 7 (3.0) 15 (3.2)
Upper respiratory tract infection bacterial 13 (5.6) 10 (2.1)
Lower respiratory tract infection 5 (2.2) 9 (1.19)
Back pain 5 (2.2) 8 (1.17)
Serious adverse events 13 (5.6) 22 (4.6)
Adjudicated CCV events
Atrial fibrillation/flutter (new onset) 0 2 (0.4)
Serious CCV events 1 (0.4) 0
MACE 0 0
From [33].The safety profiles of both LAMAs and LABAs are
well known. However, when combining the two drugs, it
is important to understand both the similarities and
differences in adverse events. Both LABAs and LAMAs
can have effects on the cardiovascular system [73,74];
these adverse events need to be monitored in develop-
ment programs for combination products.
Results suggest that the cardiovascular safety profile
of the fixed combination glycopyrronium/indacaterol
(QVA149) is similar to placebo, with no clinically sig-
nificant differences observed versus placebo [75].
In SHINE [33] and ENLIGHTEN [68] studies QVA149
was well tolerated over the 26 and 52 -week study, re-
spectively, with an adverse events profile similar to that of
placebo (Table 1). In addition, no actual or potential safety
issues were observed with the combination compared with
the single bronchodilators. The ILLUMINATE study
compared the efficacy, safety, and tolerability of QVA149
versus salmeterol–fluticasone (SFC) over 26 weeks in
patients with moderate-to-severe COPD, and the overall
incidence of adverse events was similar for QVA149 and
SFC treatment groups [70]. No untoward safety findings
were apparent with the QVA149 approach compared
with the single LAMA treatments (Glycopyrronium or
Tiotropium) investigated in the SPARK study [69], all
treatments were well tolerated and had acceptable pro-
files of cardio-cerebrovascular safety. Finally, the BEACON
study [76] demonstrated that once-daily QVA149 provides
an efficacy and safety profile similar to the concurrent
administration of its monocomponents indacaterol and
glycopyrronium.iscontinuations over the 26-weeks treatment period
Indacaterol 150 μg Glycopyrronium 50 μg Tiotropium 18 μg
476 473 480
291 (61.1) 290 (61.3) 275 (57.3)
153 (32.1) 150 (31.7) 138 (28.8)
35 (7.4) 46 (9.7) 40 (8.3)
38 (8.0) 18 (3.8) 21 (4.4)
32 (6.7) 20 (4.2) 24 (5.0)
7 (1.5) 10 (2.1) 10 (2.1)
11 (2.3) 13 (2.7) 12 (2.5)
13 (2.7) 15 (3.2) 22 (4.6)
15 (3.2) 7 (1.5) 12 (2.5)
11 (2.3) 17 (3.6) 8 (1.7)
26 (5.5) 29 (6.1) 19 (4.0)
3 (0.6) 2 (0.4) 1 (0.2)
6 (1.3) 7 (1.5) 4 (0.8)
2 (0.4) 3 (0.6) 3 (0.6)
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The current guidelines recommend the addition of a
second bronchodilator to the initial therapy of moderate
COPD, in order to maximize bronchodilation.
There have been clinical trials on the following
combinations
 Formoterol + tiotropium
 Arformoterol or nebulized formoterol + tiotropium
 Salmeterol + tiotropium
 Indacaterol + tiotropium
 Indacaterol + glycopyrronium
Aaron and Coll, in 2007, published the results of the
Optimal study, in which the effects of two bronchodila-
tion treatments on FEV1were studied. The patients were
divided in two groups: tiotropium + placebo in one
group and tiotropium + salmeterol in the second group
[77]. The FEV1 pre-broncodilator was shown to be
superior in the tiotropium + salmeterol group, in all the
evaluations, completed at 4, 20, 36, and 54 weeks. The
group with double bronchodilation, furthermore, suffered
a lower number of bronchitic relapses.
Similarly, there was a significant improvement in quality
of life (SGRQ) with the double bronchodilation.
Mahler, in 2012, published data related to the INTRUST
1 and 2 studies, in which indacaterol 150 μguid + tiotropium
18 μguid was demonstrated to be significantly superior to
tiotropium 18 μguid, evaluating both the standardized AUC
of FEV1 from 5 minutes to 8 hours after the dose at the 12
th
week, as well as the difference in FEV1 at the 12
th week [78].
Finally, Vincken et al. showed that in patients with
moderate-to-severe COPD, once-daily coadministration
of indacaterol and glycopirronium provides significant
and sustained improvement in bronchodilation versus
single broncodilator from day 1, with significant im-
provements in patient-centered outcomes [79].
After evaluating the results of the trials in which one
bronchodilator was compared to the association of a
beta adrenergic + an antimuscarinic, van der Molen in
2012 came to the following conclusions [80].
With respect to mono-therapy, the combined LABA +
LAMA therapy:
 Improves breathing capacity and reduces hyperinflation
 Improves dyspnea
 Has a positive impact on the scores for evaluation of
symptoms and on the use of rescue medications
 Is usually well tolerated
Conclusions
The choice of an inhaled drug, perhaps more so than for
other drugs, must take carefully into consideration three
parameters: effectiveness, tolerability, and compliance.After a close analysis of the scientific evidence, there is
no doubt that bronchodilators have an essential role in
the treatment of COPD.
Whether these are LABA, LAMA, or the combination
of both, they are the first-line therapy to be used in
fighting the progression of COPD as are, for example,
inhaled corticosteroids in the treatment of an asthmatic
patient.
In addition to the recent scientific evidence, the na-
tional and international guidelines and the recommenda-
tions for the use of the drugs, suggest using one or
combined bronchodilators (LABA, LAMA or LABA +
LAMA) as baseline therapy, drawing attention to the
importance of maximizing bronchodilation.
To increase bronchodilation while simplifying adher-
ence in COPD therapy a fixed combination could be the
best option, which to-day is not available, unless the
physician prescribes the two drugs separately.
In particular, indacaterol (ultra-LABA) and glycopyrro-
nium (LAMA) are the most recent bronchodilators in
monosomministration available and their pre-prepared
combination (LABA/LAMA) has been approved by the
European regulatory authorities in 2013. This has dem-
onstrated statistically significant effectiveness on the key
clinical outcomes, a good tolerability profile together with
a good therapeutic compliance due to the single daily
dose. While waiting for further confirmations, a fixed
combination combining indacaterol (ultra-LABA) and
glycopyrronium (LAMA) promises to be at the moment
the only option to get optimal bronchodilation with uid
administration in COPD.
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